Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase

NCT00248404 is registered in ClinicalTrials.gov with Kiadis Pharma as lead sponsor.

NCT NCT00248404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00248404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase
Lead sponsor
Kiadis Pharma
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2005
Completion date
December 12, 2007
Enrollment
155 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tumors